Supplements

Resource
Article
CSPI Cites Adulteration, Lack of Effectiveness, and Risk of Bleeding in Letter to FDA
Article
Warning Letters Follow CSPI Investigation and Request for Enforcement Action

Resource
Article
CSPI Investigation Shows Manufacturers Can’t Support Claims